OTCMKTS:CGNH - CardioGenics Stock Price, Price Target & More

$0.0180 0.00 (-4.26 %)
(As of 04/26/2018 09:14 AM ET)
Previous Close$0.0188
Today's Range$0.0131 - $0.0180
52-Week Range$0.0034 - $0.0330
Volume50,100 shs
Average Volume170,496 shs
Market Capitalization$1.73 million
P/E RatioN/A
Dividend YieldN/A

About CardioGenics (OTCMKTS:CGNH)

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

Receive CGNH News and Ratings via Email

Sign-up to receive the latest news and ratings for CGNH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Business services, not elsewhere classified


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares96,050,000

How to Become a New Pot Stock Millionaire

CardioGenics (OTCMKTS:CGNH) Frequently Asked Questions

What is CardioGenics' stock symbol?

CardioGenics trades on the OTCMKTS under the ticker symbol "CGNH."

Who are some of CardioGenics' key competitors?

Who are CardioGenics' key executives?

CardioGenics' management team includes the folowing people:
  • Dr. Yahya Abdul Gawad MB, Ch.B., M.D., MSc., Chief Exec. Officer and Director (Age 60)
  • Mr. James A. Essex CA, MBA, Chief Financial Officer (Age 69)
  • Ms. Linda J. Stering F.Inst.L.C.O., Sec. and Director (Age 57)

Has CardioGenics been receiving favorable news coverage?

News coverage about CGNH stock has been trending positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CardioGenics earned a media sentiment score of 0.27 on Accern's scale. They also assigned news articles about the company an impact score of 46.74 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of CardioGenics?

Shares of CGNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CardioGenics' stock price today?

One share of CGNH stock can currently be purchased for approximately $0.0180.

How big of a company is CardioGenics?

CardioGenics has a market capitalization of $1.73 million.

How can I contact CardioGenics?

CardioGenics' mailing address is 6295 Northam Drive Unit 8, Mississauga A6, L4V 1W8. The company can be reached via phone at 905-673-8501 or via email at [email protected]

MarketBeat Community Rating for CardioGenics (CGNH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about CardioGenics and other stocks. Vote "Outperform" if you believe CGNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CardioGenics (OTCMKTS:CGNH) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/26/2016 forward)


CardioGenics (OTCMKTS:CGNH) Earnings History and Estimates Chart

Earnings by Quarter for CardioGenics (OTCMKTS:CGNH)

CardioGenics (OTCMKTS CGNH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/23/2015Q3 2015($0.01)ViewN/AView Earnings Details
1/31/2012Q4 2011($0.01)($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


CardioGenics (OTCMKTS:CGNH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CardioGenics (OTCMKTS CGNH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 41.40%
Insider Trading History for CardioGenics (OTCMKTS:CGNH)

CardioGenics (OTCMKTS CGNH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2015J Neil TabatznikDirectorBuy959,039$0.11$105,494.29View SEC Filing  
2/5/2015James EssexCFOBuy461,575$0.11$50,773.25View SEC Filing  
2/5/2015Linda J SterlingInsiderBuy281,162$0.11$30,927.82View SEC Filing  
2/5/2015Yahia GawadCEOBuy1,896,246$0.11$208,587.06View SEC Filing  
(Data available from 1/1/2013 forward)


CardioGenics (OTCMKTS CGNH) News Headlines


SEC Filings

CardioGenics (OTCMKTS:CGNH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


CardioGenics (OTCMKTS:CGNH) Income Statement, Balance Sheet and Cash Flow Statement


CardioGenics (OTCMKTS CGNH) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.